Canada's Alethia raises series A as it nears clinic
This article was originally published in Scrip
Executive Summary
Alethia Biotherapeutics, a Montreal-based antibody company, has closed a Can$9.6 million ($9.1 million) series A round to advance its lead programmes into clinical development over the next 18 months.